Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 22;18(1):246.
doi: 10.1186/s13075-016-1147-2.

The association of low complement with disease activity in systemic sclerosis: a prospective cohort study

James Esposito  1   2 , Zoe Brown  2 , Wendy Stevens  2 , Joanne Sahhar  3   4 , Candice Rabusa  2 , Jane Zochling  5 , Janet Roddy  6 , Jennifer Walker  7 , Susanna M Proudman  8   9 , Mandana Nikpour  10   11
Affiliations

The association of low complement with disease activity in systemic sclerosis: a prospective cohort study

James Esposito et al. Arthritis Res Ther. .

Abstract

Background: In some rheumatic diseases such as systemic lupus erythematosus (SLE), low serum complement ('hypocomplementaemia') is a feature of active disease. However, the role of hypocomplementaemia in systemic sclerosis (SSc) is unknown. We sought to determine the frequency, clinical associations and relationship to disease activity of hypocomplementaemia in SSc.

Methods: The study included 1140 patients fulfilling the 2013 American College of Rheumatology criteria for SSc. Demographic, serological and clinical data, obtained prospectively through annual review, were analysed using univariable methods. Linear and logistic regression, together with generalised estimating equations, were used to determine the independent correlates of hypocomplementaemia ever, and at each visit, respectively.

Results: At least one episode of hypocomplementaemia (low C3 and/or low C4) occurred in 24.1 % of patients over 1893 visits; these patients were more likely to be seropositive for anti-ribonucleoprotein (OR = 3.8, p = 0.002), anti-Ro (OR = 2.2, p = 0.002), anti-Smith (OR = 6.3, p = 0.035) and anti-phospholipid antibodies (OR = 1.4, p = 0.021) and were more likely to display features of overlap connective tissue disease, in particular polymyositis (OR = 16.0, p = 0.012). However, no association was found between hypocomplementaemia and either the European Scleroderma Study Group disease activity score or any of its component variables (including erythrocyte sedimentation rate) in univariate analysis. Among patients with SSc overlap disease features, those who were hypocomplementaemic were more likely to have digital ulcers (OR = 1.6, p = 0.034), tendon friction rubs (OR = 2.4, p = 0.037), forced vital capacity <80 % predicted (OR = 2.9, p = 0.008) and lower body mass index (BMI) (OR for BMI = 0.9, p < 0.0005) at that visit, all of which are features associated with SSc disease activity and/or severity.

Conclusions: While hypocomplementaemia is not associated with disease activity in patients with non-overlap SSc, it is associated with some features of increased SSc disease activity in patients with overlap disease features.

Keywords: Complement; Disease activity; Systemic sclerosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design. EScSG European Scleroderma Study Group, SSc Systemic sclerosis
See this image and copyright information in PMC

References

    1. Nikpour M, Stevens WM, Herrick AL, Proudman SM. Epidemiology of systemic sclerosis. Best Pract Res Clin Rheumatol. 2010;24(6):857–69. doi: 10.1016/j.berh.2010.10.007. - DOI - PubMed
    1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989–2003. doi: 10.1056/NEJMra0806188. - DOI - PubMed
    1. Medsger TA., Jr Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am. 2003;29(2):255–73. doi: 10.1016/S0889-857X(03)00023-1. - DOI - PubMed
    1. Symmons DPM. Disease assessment indexes: activity, damage and severity. Baillieres Clin Rheumatol. 1995;9(2):267–85. doi: 10.1016/S0950-3579(05)80190-6. - DOI - PubMed
    1. Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol. 2002;29(2):288–91. - PubMed

Publication types